production of high-volume
recombinant therapeutic
proteins in the white of
transgenic chicken eggs.
An effectively priced alternative that:
- Increases your flexibility,
- Is truly scalable,
- Improves your time to market,
- Lowers your capital requirements, and thus
- Improves your bottom line.
Any statements contained within this website which are not historical facts, including projections or statements
concerning capabilities, plans, results and the expected benefits to be derived there from, are forward looking
statements that involve risks and uncertainties as identified in TranXenoGen’s disclosure documents filed with the
U.K. Alternative Investment Market of the London Stock Exchange. The Company does not undertake any obligation
to update forward looking statements. The Company’s shares have not been registered under the U.S. Securities
Act of 1933, as amended (“the Securities Act”) and are “restricted securities” as defined in Rule 144 promulgated
under the Securities Act.
NEWS CENTER I CAREERS I CONTACT US I DIRECTIONS
TRANXENOGEN, INC. • PO BOX 21 • NORTHBORO, MA. 01532 • 508 842 5036
© COPYRIGHT TRANXENOGEN, INC. 2002